Expert Review of Anti-Infective Therapy

Papers
(The TQCC of Expert Review of Anti-Infective Therapy is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies172
Azithromycin in the treatment of COVID-19: a review160
COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up153
Resolution of coronavirus disease 2019 (COVID-19)116
An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications104
The use of IV vitamin C for patients with COVID-19: a case series98
Sepsis-associated encephalopathy and septic encephalitis: an update95
Antimicrobial resistance in low- and middle-income countries: current status and future directions87
Exercise and well-being during COVID 19 – time to boost your immunity77
Quorum quenching enzymes and their effects on virulence, biofilm, and microbiomes: a review of recent advances76
Functionalized carbon-based nanomaterials and quantum dots with antibacterial activity: a review71
Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination65
Can nanotechnology help in the fight against COVID-19?65
COVID-19: fighting the invisible enemy with microRNAs63
Calycosin: a Review of its Pharmacological Effects and Application Prospects62
Moxidectin: an oral treatment for human onchocerciasis53
Virulence factors, antibiotic resistance patterns, and molecular types of clinical isolates of Klebsiella Pneumoniae51
CAR-T cell therapy and infection: a review49
Update on the epidemiology of carbapenemases in Latin America and the Caribbean48
Point prevalence surveys of antimicrobial use: a systematic review and the implications47
COVID-19 and vitamin D (Co-VIVID study): a systematic review and meta-analysis of randomized controlled trials45
Current and emerging strategies to combat antimalarial resistance44
Antimicrobial consumption in patients with COVID-19: a systematic review and meta-analysis44
Old and re-purposed drugs for the treatment of COVID-1944
Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management42
Progress on the national action plan of Pakistan on antimicrobial resistance (AMR): a narrative review and the implications36
MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale35
Loss of smell and taste: a new marker of COVID-19? Tracking reduced sense of smell during the coronavirus pandemic using search trends34
Bacterial death from treatment with fluoroquinolones and other lethal stressors33
Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-233
Tackling Antimicrobial Resistance by promoting Antimicrobial stewardship in Medical and Allied Health Professional Curricula32
All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies31
Antibiotic resistant bacteria: current situation and treatment options to accelerate the development of a new antimicrobial arsenal31
A point prevalence survey of antimicrobial utilisation patterns and quality indices amongst hospitals in South Africa; findings and implications31
Fungal sphingolipids: role in the regulation of virulence and potential as targets for future antifungal therapies30
Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old drugs30
Diagnostic accuracy of the Xpert MTB/RIF assay for abdominal tuberculosis: a systematic review and meta-analysis30
Nanomaterials as drug delivery systems with antibacterial properties: current trends and future priorities29
Addressing antimicrobial resistance in Nigerian hospitals: exploring physicians prescribing behavior, knowledge, and perception of antimicrobial resistance and stewardship programs29
Topical delivery of growth factors and metal/metal oxide nanoparticles to infected wounds by polymeric nanoparticles: an overview28
Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection28
Vitamin D attenuates COVID-19 complications via modulation of proinflammatory cytokines, antiviral proteins, and autophagy28
Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study28
Use of Xpert MTB/RIF and Xpert Ultra in extrapulmonary tuberculosis27
RETRACTED ARTICLE: Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study27
Management strategies for human babesiosis27
Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis27
Multidrug-resistant Klebsiella pneumoniae: mechanisms of resistance including updated data for novel β-lactam-β-lactamase inhibitor combinations27
A review on favipiravir: the properties, function, and usefulness to treat COVID-1926
Bacteria and fungi as major bio-sources to fabricate silver nanoparticles with antibacterial activities26
Antibiotic consumption among hospitalized neonates and children in Punjab province, Pakistan25
Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational mult25
Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies24
Incidence and risk factors of carbapenem-resistantEnterobacteriaceaeinfection in intensive care units: a matched case–control study23
Therapeutic strategies to address monkeypox23
Dengue vaccine: an update23
Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine – from HIV-1 infection to COVID-1922
Quorum sensing: a new prospect for the management of antimicrobial-resistant infectious diseases22
Nanotechnology-based promising strategies for the management of COVID-19: current development and constraints22
Proposed amendments regarding the definitions of multidrug-resistant and extensively drug-resistant bacteria22
Therapeutic drug monitoring of β-lactam antibiotics in the ICU22
Possible therapeutic agents for COVID-19: a comprehensive review22
Role of vacuolating cytotoxin A in Helicobacter pylori infection and its impact on gastric pathogenesis21
Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges21
Benznidazole for the treatment of Chagas disease21
Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress21
A systematic literature review to assess the burden of herpes zoster disease in China20
Helminths, hosts, and their microbiota: new avenues for managing gastrointestinal helminthiases in ruminants20
Cardiovascular disease in HIV patients: recent advances in predicting and managing risk20
Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease19
A multicentre point prevalence survey of hospital antibiotic prescribing and quality indices in the Kurdistan regional government of Northern Iraq: the need for urgent action19
Detection of SARS-CoV-2 by antigen ELISA test is highly swayed by viral load and sample storage condition19
NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects18
Impact of bacterial infections on erythropoiesis18
A review of current treatment strategies for infective endocarditis17
Recent advances in the understanding of enterovirus A71 infection: a focus on neuropathogenesis17
Quadruple therapy for asymptomatic COVID-19 infection patients17
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams17
Implementation of antimicrobial stewardship to reduce antimicrobial drug resistance16
The democratization of de-labeling: a review of direct oral challenge in adults with low-risk penicillin allergy16
The war against bacteria, from the past to present and beyond16
Non-antibiotic antibacterial peptides and proteins of Escherichia coli: efficacy and potency of bacteriocins16
Treatment of carbapenem-resistantPseudomonas aeruginosainfections: a case for cefiderocol16
Treatment strategies for OXA-48-like and NDM producing Klebsiella pneumoniae infections16
Knowledge, attitude and practices among consumers toward antibiotics use and antibiotic resistance in Swat, Khyber-Pakhtunkhwa, Pakistan15
Healthcare-associated ventriculitis: current and emerging diagnostic and treatment strategies15
Drug repurposing: new strategies for addressing COVID-19 outbreak15
A multicentre point prevalence study of antibiotics utilization in hospitalized patients in an urban secondary and a tertiary healthcare facilities in Nigeria: findings and implications15
Fostemsavir for the treatment of HIV15
Acanthamoeba Keratitis: an update on amebicidal and cysticidal drug screening methodologies and potential treatment with azole drugs15
Adjuvant use of combination of antibiotics in acute severe ulcerative colitis: A placebo controlled randomized trial15
Intravenous fosfomycin for the treatment of patients with central nervous system infections: evaluation of the published evidence15
Drug discovery for primary amebic meningoencephalitis: from screen to identification of leads15
Public knowledge, attitude, and practice regarding antibiotics use in Punjab, Pakistan: a cross-sectional study15
Integrative role of traditional and modern technologies to combat COVID-1914
‘Secondary prevention’ against female HPV infection: literature review of the role of carrageenan14
Cryptococcal meningitis: a review of cryptococcal antigen screening programs in Africa14
Diagnosis of clinical malaria in endemic settings14
Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review14
Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections14
Endemic mycoses: epidemiology and diagnostic strategies14
Caspofungin: a review of its characteristics, activity, and use in intensive care units14
Managing sepsis in the era of precision medicine: challenges and opportunities14
Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV14
The rise of mucormycosis in Covid-19 patients in India14
Predictors of mortality in invasive pneumococcal disease: a meta-analysis14
Current rates of purchasing of antibiotics without a prescription across sub-Saharan Africa; rationale and potential programmes to reduce inappropriate dispensing and resistance13
Corticosteroids in SARS-COV2 infection: certainties and uncertainties in clinical practice13
Knowledge, attitude, and practices of community pharmacy staff toward antimicrobial stewardship programs: a cross-sectional study from Northeastern China13
Bacteriophages for ESKAPE: role in pathogenicity and measures of control13
Diagnosis, prevention, and treatment of coronavirus disease: a review13
Evaluation of favipiravir in the treatment of COVID-19 based on the real-world13
Anti-inflammatory effects of GLP-1 in patients with COVID-1912
Adolescents and young adults with early acquired HIV infection in the united states: unique challenges in treatment and secondary prevention12
Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review12
COVID-19 and cardiovascular complications: an update from the underlying mechanism to consequences and possible clinical intervention12
Antifungal susceptibility testing in Candida species: current methods and promising new tools for shortening the turnaround time12
Porphyromonas gingivalis infection may contribute to systemic and intracerebral amyloid-beta: implications for Alzheimer’s disease onset12
An update on endotoxin neutralization strategies in Gram-negative bacterial infections12
Precision medicine for the diagnosis and treatment of carbapenem-resistant Enterobacterales: time to think from a different perspective12
Molecular diagnosis of toxoplasmosis: recent advances and a look to the future12
Inflammation in neurocysticercosis: clinical relevance and impact on treatment decisions12
The potential for CXCL13 in CSF as a differential diagnostic tool in central nervous system infection12
Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: an observational prospective open label user survey11
Self-medication Behavior with antibiotics: a national cross-sectional survey in Sri Lanka11
The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives11
Streptogramins for the treatment of infections caused by Gram-positive pathogens11
Lifestyle and rehabilitation during the COVID-19 pandemic: guidance for health professionals and support for exercise and rehabilitation programs11
Exacerbation of antimicrobial resistance: another casualty of the COVID-19 pandemic?11
Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?11
Global travel and Gram-negative bacterial resistance; implications on clinical management11
Novel strategies for rapid identification and susceptibility testing of MRSA11
Host–pathogen interaction inCandida glabratainfection: current knowledge and implications for antifungal therapy11
Potential utility of nano-based treatment approaches to address the risk ofHelicobacter pylori11
Clinical impact of procalcitonin-based algorithms for duration of antibiotic treatment in critically ill adult patients with sepsis: a meta-analysis of randomized clinical trials11
Sepsis in the critically ill patient: current and emerging management strategies11
The antifungal activity of caspofungin in combination with antifungals or non-antifungals against Candida species in vitro and in clinical therapy11
0.031980991363525